Figure 10.

AQTGTGKT peptide increases the expression of miR-143-3p and miR-373-5p to confer sensitivity to anti-cancer drugs. (A) Total RNAs isolated from the indicated cancer cells were subjected to miRNA array analysis. PC-9/ER cells were transfected without or with AQTGTGKT (10 μM) for 24 h. (B) PC-9 cells were transfected with the indicated inhibitor (each at 10 nM). At each time point after transfection, cell lysates were isolated and subjected to immunoblot. (C) PC-9 cells were transfected with the indicated inhibitor (each at 10 nM) for 48 h, followed by immunoprecipitation. (D) PC-9 cells were transfected with the indicated inhibitor without or with AQTGTGKT peptide. On the next day, cells were then treated without or with erlotinib (20 μM) or osimertinib (5 μM) for 24 h, followed by immunoblot. (E) PC-9 cells were transfected with the indicated inhibitor (each at 10 nM) without or with AQTGTGKT peptide (10 μM). At 48 h after transfection, immunoblot was performed.